Christina Mattina

Biomarker testing is critical for determining optimal therapy early in the non–small lung cancer (NSCLC) treatment process, but research shows uneven insurance coverage of these tests and inconsistent uptake in cancer centers.

Speakers at the 2024 World Conference on Lung Cancer discussed the considerations that must go into designing and performing clinical trials in the early-stage lung cancer space, ranging from selecting an end point to empowering participants.

Clinicians, researchers, and payer experts convened in Aurora, Colorado, on August 13, 2024, for discussions on ensuring that the recent advancements in lipid management are making their way to patients.

The toxicity of lung cancer treatment has traditionally been discussed in terms of physical symptoms, but there is a growing focus on financial toxicity, time toxicity, and other effects on well-being, as reflected in research presented at the 2024 World Conference on Lung Cancer.

Isatuximab (Sarclisa) with bortezomib, lenalidomide, and dexamethasone (VRd) is now an approved option for adults who cannot receive an autologous stem cell transplant to treat their newly diagnosed multiple myeloma.

In the PANORAMA-HF trial, children receiving sacubitril/valsartan for their heart failure experienced clinically meaningful improvements similar to those seen in children receiving enalapril, although the former may provide an edge on quality of life.

Former President Donald J. Trump's return to the White House portends a significant shakeup of health policy.

President-elect Donald J. Trump has announced his selection of Robert F. Kennedy Jr as his chosen nominee for secretary of HHS—a role in which the vaccine skeptic could wield enormous influence over public health.

In 2024, the most-read articles published in our flagship peer-reviewed journal, The American Journal of Managed Care® (AJMC®), touched on disease burden, policy consequences, and more.

In 2024, the most-read articles published in Population Health, Equity & Outcomes (PHEO) highlighted the promise of accountable care, coverage challenges for obesity therapies, and much more.